文献速递流行病学与生物统计临床试验与 GCP

他汀治疗对肌肉症状的影响:大规模随机双盲试验的个体参与者数据荟萃分析

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
PubMed 文献 · Lancet · 2022-08-29

该研究汇总了19项他汀与安慰剂对照试验(n=123940)和4项强化与中等强度他汀方案对比试验(n=30724)的个体参与者数据。结果显示,他汀组肌肉疼痛或无力报告率略高于安慰剂组(27.1% vs 26.6%,RR 1.03,95%CI 1.01-1.06),第一年相对增加7%,绝对超额率为每1000人年11例(6-16),此后无显著超额。作者结论为他汀引起的肌肉症状超额风险很小且多数轻微,远低于已知心血管获益,需重新审视临床管理。

要点

  • 他汀组27.1% vs 安慰剂组26.6%报告肌肉疼痛或无力,RR 1.03(95%CI 1.01-1.06)。
  • 第一年他汀治疗相对增加7%肌肉症状,绝对超额率每1000人年11例(6-16)。
  • 第一年后无显著超额报告(RR 0.99,95%CI 0.96-1.02)。

核心结论

  • 他汀治疗引起少量主要为轻度的肌肉疼痛超额风险。
  • 他汀组报告的肌肉症状中绝大多数(>90%)并非由他汀引起。
  • 肌肉症状的微小风险远低于已知的心血管获益。
  • 需要重新审视服用他汀患者肌肉症状的临床管理。

研究设计与样本

  • 纳入标准为计划招募至少1000例参与者、预定治疗时长至少2年、双盲比较他汀与安慰剂或强化与较弱他汀方案的随机试验。
  • 分析了19项他汀与安慰剂双盲试验(n=123940)和4项强化与较弱他汀方案双盲试验(n=30724)的个体参与者数据。
  • 按预设方案对肌肉结局进行标准逆方差加权荟萃分析。

主要发现

  • 19项安慰剂对照试验中,平均年龄63岁(SD 8),女性34533例(27.9%),既往血管疾病59610例(48.1%),糖尿病22925例(18.5%)。
  • 加权平均中位随访4.3年,他汀组16835例(27.1%)vs 安慰剂组16446例(26.6%)报告肌肉疼痛或无力,RR 1.03(95%CI 1.01-1.06)。
  • 第一年他汀治疗使肌肉疼痛或无力相对增加7%(RR 1.07,95%CI 1.04-1.10),绝对超额率每1000人年11例(95%CI 6-16),表明他汀组肌肉相关报告中仅约十五分之一([1.07-1.00]/1.07)实际由他汀引起。
  • 第一年后首次报告肌肉疼痛或无力无显著超额(RR 0.99,95%CI 0.96-1.02)。
  • 所有年份合并分析,强化他汀方案(即阿托伐他汀40-80 mg或瑞舒伐他汀20-40 mg每日一次)与安慰剂相比RR高于较弱或中等强度方案(RR 1.08,95%CI 1.04-1.13 vs RR 1.03,95%CI 1.00-1.05),强化方案第一年后存在小幅超额(RR 1.05,95%CI 0.99-1.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statin therapy is effective for the prevention of atherosclerotic cardiovascular disease and is widely prescribed, but there are persisting concerns that statin therapy might frequently cause muscle pain or weakness. We aimed to address these through an individual participant data meta-analysis of all recorded adverse muscle events in large, long-term, randomised, double-blind trials of statin therapy. METHODS: Randomised trials of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment duration of at least 2 years, and involved a double-blind comparison of statin versus placebo or of a more intensive versus a less intensive statin regimen. We analysed individual participant data from 19 double-blind trials of statin versus placebo (n=123 940) and four double-blind trials of a more intensive versus a less intensive statin regimen (n=30 724). Standard inverse-variance-weighted meta-analyses of the effects on muscle outcomes were conducted according to a prespecified protocol. FINDINGS: Among 19 placebo-controlled trials (mean age 63 years [SD 8], with 34 533 [27·9%] women, 59 610 [48·1%] participants with previous vascular disease, and 22 925 [18·5%] participants with diabetes), during a weighted average median follow-up of 4·3 years, 16 835 (27·1%) allocated statin versus 16 446 (26·6%) allocated placebo reported muscle pain or weakness (rate ratio [RR] 1·03; 95% CI 1·01-1·06). During year 1, statin therapy produced a 7% relative increase in muscle pain or weakness (1·07; 1·04-1·10), corresponding to an absolute excess rate of 11 (6-16) events per 1000 person-years, which indicates that only one in 15 ([1·07-1·00]/1·07) of these muscle-related reports by participants allocated to statin therapy were actually due to the statin. After year 1, there was no significant excess in first reports of muscle pain or weakness (0·99; 0·96-1·02). For all years combined, more intensive statin regimens (ie, 40-80 mg atorvastatin or 20-40 mg rosuvastatin once per day) yielded a higher RR than less intensive or moderate-intensity regimens (1·08 [1·04-1·13] vs 1·03 [1·00-1·05]) compared with placebo, and a small excess was present (1·05 [0·99-1·12]) for more intensive regimens after year 1. There was no clear evidence that the RR differed for different statins, or in different clinical circumstances. Statin therapy yielded a small, clinically insignificant increase in median creatine kinase values of approximately 0·02 times the upper limit of normal. INTERPRETATION: Statin therapy caused a small excess of mostly mild muscle pain. Most (>90%) of all reports of muscle symptoms by participants allocated statin therapy were not due to the statin. The small risks of muscle symptoms are much lower than the known cardiovascular benefits. There is a need to review the clinical management of muscle symptoms in patients taking a statin. FUNDING: British Heart Foundation, Medical Research Council, Australian National Health and Medical Research Council.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022. PMID: 36049498. doi:10.1016/S0140-6736(22)01545-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。